Dose-escalation Study of Safety of PBCAR19B in Participants With CD19-expressing Malignancies

A Phase 1 Study of PBCAR19B in Participants With CD19-expressing Malignancies

This is a Phase 1, nonrandomized, open-label, single-dose, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of PBCAR19B in adult study participants with CD-19 expressing malignancies.

Inclusion Criteria:

• Relapsed or refractory CD19+ expressing malignancies
• At least 2 prior regimens per Standard of Care

Exclusion Criteria:

• No history of active CNS involvement